These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2754876)

  • 1. [Nursing of a patient with ascites being treated with OK-432].
    Yamashita I; Hidaka M; Ikegawa H; Yuhara K; Mori C
    Kango Gijutsu; 1989 Mar; 35(4):412-5. PubMed ID: 2754876
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antitumor activity of neutrophils induced by a nonspecific immunopotentiator OK-432. II. Experimental study using human malignant ascites].
    Umemoto T; Saji S; Oonishi A; Kunii Y; Goshima H; Tachibana S; Takao H; Tanemura H; Sakata K
    Nihon Gan Chiryo Gakkai Shi; 1988 Jul; 23(7):1512-7. PubMed ID: 3183459
    [No Abstract]   [Full Text] [Related]  

  • 3. [TNF induction in the serum and ascites of a gastric cancer patient treated with OK-432].
    Neda H; Watanabe N; Sone H; Yamauchi N; Niitsu Y; Urushizaki I
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):593-7. PubMed ID: 3954382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant ascites treated with streptococcal extract.
    Lancet; 1983 Jun; 1(8336):1258. PubMed ID: 6134047
    [No Abstract]   [Full Text] [Related]  

  • 5. Advanced ovarian cancer treated by intraperitoneal immunotherapy with OK-432.
    Kawagoe K; Masuda H
    Jpn J Clin Oncol; 1986 Jun; 16(2):137-42. PubMed ID: 3735703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The management of malignant ascites with a streptococcal preparation, OK-432: relation between the clinical effect and auto-tumor cell killing activity by OK-432-induced ascites-derived lymphocytes].
    Katano M; Yamamoto H; Mizoguchi T; Hidaka K; Hisatsugu T; Torisu M
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2464-8. PubMed ID: 3497612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction.
    Katano M; Torisu M
    Surgery; 1983 Mar; 93(3):365-73. PubMed ID: 6600854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of malignant ascites. II. Immunological studies on disappearance of ascites by intraperitoneal injection of a streptococcal preparation, OK-432 (author's transl)].
    Katano M
    Fukuoka Igaku Zasshi; 1981 Oct; 72(10):543-55. PubMed ID: 7327499
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of malignant ascites. I. Clinical studies on intraperitoneal injection of a streptococcal preparation, OK-432 (author's transl)].
    Katano M
    Fukuoka Igaku Zasshi; 1981 Oct; 72(10):532-42. PubMed ID: 7327498
    [No Abstract]   [Full Text] [Related]  

  • 10. [Management of malignant ascites with a streptococcal preparation, OK-432: induction of growth inhibition factor(s) against tumor cells].
    Katano M; Yamamoto H; Hisatsugu T
    Nihon Geka Gakkai Zasshi; 1986 Apr; 87(4):471. PubMed ID: 3713694
    [No Abstract]   [Full Text] [Related]  

  • 11. Neutrophil-mediated tumor cell destruction in cancer ascites.
    Katano M; Torisu M
    Cancer; 1982 Jul; 50(1):62-8. PubMed ID: 7083126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of OK-432 in the treatment of primary lung cancer].
    Kishimoto T; Okada K
    Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival.
    Torisu M; Katano M; Kimura Y; Itoh H; Takesue M
    Surgery; 1983 Mar; 93(3):357-64. PubMed ID: 6187080
    [No Abstract]   [Full Text] [Related]  

  • 14. [Picibanil (OK 432)].
    Nekulová M; Mechl Z; Vorlíĉek J; Sopková B
    Cas Lek Cesk; 1983 May; 122(20):632-3. PubMed ID: 6850738
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of streptococcal preparation (OK-432) local injection in patients with urinary bladder carcinoma.
    Nishio S; Izeki T; Wada S; Morikawa Y; Yasumoto R; Maekawa M
    Osaka City Med J; 1980; 26(1):47-59. PubMed ID: 7267092
    [No Abstract]   [Full Text] [Related]  

  • 16. [Antitumor activity of neutrophils induced by a nonspecific immunopotentiator OK-432. I. Experimental study using a rat model of malignant ascites].
    Umemoto T; Saji S; Minatsu H; Kunii Y; Goshima H; Tachibana S; Takao H; Sakata K
    Nihon Gan Chiryo Gakkai Shi; 1988 Jun; 23(6):1229-35. PubMed ID: 3230342
    [No Abstract]   [Full Text] [Related]  

  • 17. Neutrophil-mediated tumor cell destruction in cancer ascites. II. A OK-432 attracts killer neutrophils through activation of complement C5.
    Fujimura T; Torisu M
    Clin Immunol Immunopathol; 1987 May; 43(2):174-84. PubMed ID: 3105938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Whole abdominal irradiation of ovarian cancer in combined treatment with OK-432 picibanil].
    Morita S; Arai T; Tsunemoto H
    Gan No Rinsho; 1986 Jan; 32(1):71-5. PubMed ID: 3005691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and experimental studies on a new intrabronchial infusion therapy of immunopotentiator-OK-432 in lung cancer].
    Gose K; Hirota S; Imajo Y; Adachi S; Yonezawa K; Soejima T; Takada Y; Kimura S; Tsubota N
    Nihon Gan Chiryo Gakkai Shi; 1986 Jul; 21(6):1208-16. PubMed ID: 3782973
    [No Abstract]   [Full Text] [Related]  

  • 20. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
    Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
    J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.